~~<i id='AD92D96413'><strike id='AD92D96413'><tt id='AD92D96413'><pre id='AD92D96413'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

author：focus 2025-09-02 08:24:02 - browse：953

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Morgan Health, with ambitious aims, wants you to know it’s still here

leisure time

focus

explore

hotspot

leisure time

Wikipedia

RyanPierse/GettyImagesHereisSTAT’sbiotechscorecard,ourregularledgerofstock-movingbiotechevents,forth

WSS

Surprise medical billing ban raises prices elsewhere

White House finalizes ITC's import ban of latest Apple Watches

3 trends to watch in health tech's hiring outlook for 2024

Flagship Pioneering startup Sonata Therapeutics lays off 21

3 trends to watch in health tech's hiring outlook for 2024

Flagship Pioneering startup Sonata Therapeutics lays off 21

focus

focus

leisure time

Alkermes shareholders re

Weight loss drugs aren’t covered by Obamacare. That may change

Continuity nursing helped my family in our darkest PICU moments

Secretariat’s lessons for human medicine

Moonlake's readout produced a cash windfall. Risks remain

New study raises questions about niacin and heart health

How one medical school became remarkably diverse

J&J to buy cancer drug developer Ambrx Biopharma

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

In 'major milestone,' FDA approves first cell therapy for solid tumors

Surprise medical billing ban raises prices elsewhere

Burning questions for the 2024 JPM Healthcare Conference

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

A single drug, study failures leave Anavex with nothing but cash

Ukraine seeks to reclaim its role as a hub for clinical trials

explore

hotspot

leisure time

Wikipedia